+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CoMentis Inc - logo

CoMentis specializes in the development of small-molecule drugs to treat neurovascular diseases with a focus on Alzheimer's disease and schizophrenia. They cover the research and development spectrum from initial drug design through manufacturing and clinical trials. The company, with headquarters in South San Francisco, was formed by the merger of Zapaq, Inc. and Athenagen, Inc. in 2006. It is also working on nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders.

Beta Secretase Inhibitor - Pipeline Insight, 2022 - Product Thumbnail Image

Beta Secretase Inhibitor - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
From
From
From
Endotoxemia Global Clinical Trials Review, H1, 2019 - Product Thumbnail Image

Endotoxemia Global Clinical Trials Review, H1, 2019

  • Clinical Trials
  • May 2019
  • 66 Pages
From
  • 7 Results (Page 1 of 1)
Loading Indicator